Portal Notfall Aufnahme

Universitätsklinik für Innere Medizin – Onkologie und Hämatologie


Zahlen, Daten, Fakten

48 stationäre Betten
10 teilstationäre Betten
3 Stationen
104 Mitarbeiterinnen & Mitarbeiter

Im Jahr 2019

915Behandlungsfälle (DRG)
153teilstationäre Behandlungstage
114Knochenmarktransplantationen
insgesamt, davon...
78autologe Stammzelltransplantationen
36allogene Stammzelltransplantationen


Ärztliches Team

 

Leitender Arzt

Prof. Dr. med. Jochen Casper

 

Vertreter des Klinikdirektors
Leitender Arzt für allogene Stammzelltransplantation

Facharzt für Innere Medizin, Schwerpunkt Hämatologie und Internistische Onkologie
Palliativmedzin

Telefon: (0441) 403-2614

Telefax: (0441/403-2892

E-Mail: casper.jochen@klinikum-oldenburg.de


Beruflicher Lebenslauf:

Name:Prof.Dr.med. Jochen Casper
Gegenwärtige Positionen:

Leitender Arzt - allogene Blut Stammzelltransplantation

Stellvertretender Klinikdirektor, Universitätsklilnik für Innere Medizin - Onkologie und Hämatologie

Vorsitzender der Arzneimittelkommission Klinikum Oldenburg

Vorherige Positionen:
1983 – 1985Assistenzarzt, Medizinische Hochschule Hannover
1985 – 1987Postdoctoral Scientist, Southwest Foundation for Biomedical Research, San Antonio, Texas
1987 – 1993Assistenzarzt, Medizinische Hochschule Hannover
1993 – 1995Facharzt, Medizinische Hochschule Hannover
1995 – 2007Stellvertretender Klinikdirektor, Klinik für Hämatologie und Onkologie, Universität Rostock
Ausbildung:
1977 – 1983Medizinstudium , Medizinische Hochschule Hannover
1983 – 1985Innere Medizin, Hämatologie und internistische Onkologie, Medizinische Hochschule Hannover
1985 – 1987Postdoctoral Scientist, Southwest Foundation for Biomedical Research, Dep. for Virology and Immunology, San Antonio, Texas
1987 – 1993Innere Medizin, Hämatologie und internistische Onkologie, Medizinische Hochschule Hannover
1993 – 1995Hämatologie und internistische Onkologie, Medizinische Hochschule Hannover
Qualifikationen:
1983Approbation
1985Promotion “summa cum laude”
1993Facharzt für Innere Medizin
1995Facharzt für Hämatologie und internistische Onkologie
1997Habilitation Innere Medizin
2007Zusatzbezeichung Palliativmedizin
Sprechstunden:
  • KV Ermächtigungsambulanz: Vorbereitung und
  • Nachsorge der allogenen Blutstammzell-transplantation
  • Privatsprechstunde für Patienten mit hämatologischen Erkrankungen
Mitgliedschaften:
  • Deutsche Gesellschaft für Hämatologie und Onkologie
  • Deutsche Krebsgesellschaft
  • Europäische Blut- und Knochenmarktransplantationsgesellschaft (EBMT)
  • Deutsche Arbeitsgemeinschaft für Blut- und Knochenmarktransplantation (DAG-KBT)
  • Ostdeutsche Studiengruppe Onkologie
Gegenwärtige Forschungs-schwerpunkte:
  • Toxizitätsreduzierte Konditionierungsverfahren bei allogener Blutstammzelltransplantation
  • Therapie des metastasierten Nierenkarzinoms


Veröffentlichungen:

  1. Pazopanib versus Sunitini b in renal cancer.
    Casper J, Schumann-Bi narsch 5, Köhne CH.
    N Engl J Med. 2013 Nov 14;369(20):1969.
  2. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stern cell transplantation.
    Metzner B, Pott C, Müller TH, Gebauer W, Casper J, Kraemer D, Rosien B, Schumann-Binarsch 5, Thole R, Köhne CH. 
    Ann Oncol. 2013 Jun;24(6):1609-15.
  3. Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stern cell transplantation.
    Kahl C, Sayer HG, Hinke A, Freund M, Casper J.
    J Cancer Res Clin Oncol. 2012 Mar;138(3):513-7.
  4. Allogeneic hematopoietic SCT in patients with AML following
    treosulfan/fludarabine conditioning. Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T, volin L, Einsele H, Stuhler G, Uharek L, Blau I, Bornhaeuser M, Zander AR,Larsson K, Markiewicz M, Giebels, Kruzel T, Mylius HA, Baumgart J, Pichlmeier u, Freund M, Beelen DW. 
    Bone Marrow Transplant. 2012
    Sep;47(9):1171-7.
  5. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
    Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, Holowiecki J, Giebel S, Markiewicz M, Uharek L, Blau IW, Kienast J, Stelljes M, Larsson K, Zander AR, Gramatzki M, Repp R, Einsele H, Stuhler G, Baumgart J, Mylius HA, Pichlmeier U, Freund M, Casper J.
    Haematologica. 2011 Sep;96(9):1344-50. Epub 2011 Jun 9.
  6. Long-term remissions in metastatic malignant melanoma following chemotherapy and tamoxifen maintenance.
    Metzner B, Casper J, Hartung G, Rosien B, Hölzle E, Pelzer P, Köhne CH.
    Onkologie. 2011;34(4):208-9.
  7. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.
    Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn JE, Wechsler B, Pérez-Pastor G, Blomberg B, Fuzibet JG, Dubourguet F, Marinho A,
    Magnette C, Noel V, Pavic M, Casper J, Beucher AB, Costedoat-Chalumeau N, Aaron L, Salvatierra J, Graux C, Cacoub P, Delcey V, Dechant C, Bindi P, Herbaut C, Graziani G, Amoura Z, Haroche J.
    Blood. 2011 Mar 10;117(10):2778-82.
  8. Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome.
    Hilgendorf I, Wolff D, Gromke T, Trenschel R, Elmaagacli AH, Pichlmeier U, Junghanss C, Freund M, Beelen DW, Casper J.
    Bone Marrow Transplant. 2011 Apr;46(4):502-9.
  9. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kröger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeier U, Freund M.
    J Clin Oncol. 2010 Jul 10;28(20):3344-51.
  10. Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats.
    Sender V, Hofmeister-Mielke N, Sievert K, Teifke JP, Vogel H, Baumgart J, Pichlmeier U, Freund M, Casper J, Wolff D.
    Immunopharmacol Immunotoxicol. 2009;31(4):595-600.
  11. [Erdheim-Chester disease of the orbit with compressive optic neuropathy].
    Manousaridis K, Casper J, Schittkowski MP, Nizze H, Guthoff RF.
    Ophthalmologe. 2010 Mar;107(3):266-9.
  12. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
    Kahl C, Hilgendorf I, Freund M, Casper J.
    Onkologie. 2008 Sep;31(8-9):485.
  13. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
    Hilgendorf I, Wolff D, Junghanss C, Kahl C, Leithaeuser M, Steiner B, Casper J, Freund M.
    Ann Hematol. 2008 Dec;87(12):1009-12.
  14. Ovarian type surface epithelial carcinoma of the testis with delayed metastatic spread.
    Maruschke M, Schmidt W, Casper J, Hakenberg OW.
    Urol Int. 2008;81(1):119-21.
  15. Sirolimus in combination with tacrolimus in allogeneic stem cell transplantation--timing and conditioning regimen may be crucial.
    Wolff D, Andree H, Hilgendorf I, Casper J, Freund M, Junghanss C.
    Biol Blood Marrow Transplant. 2008 Aug;14(8):942-3.
  16. Perforation of the superior vena cava - a rare complication of central venous catheters.
    Jost K, Leithäuser M, Grosse-Thie C, Bartolomaeus A, Hilgendorf I, Andree H, Casper J, Freund M, Junghanss C.
    Onkologie. 2008 May;31(5):262-4.
  17. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
    Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A, Freund M, Casper J.
    Br J Haematol. 2008 Jun;142(2):284-92.
  18. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA,
    Bokemeyer C; German Testicular Cancer Study Group.
    J Clin Oncol. 2007 Dec 20;25(36):5742-7
  19. Visual deterioration after Gram-negative sepsis in neutropenia.
    Hilgendorf I, Aepinus C, Wolff D, Leithaeuser M, Junghanss C, Casper J, Freund M.
    Ann Hematol. 2008 Feb;87(2):155-7.
  20. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
    Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H, Kanz L, Keilholz U, Marinets O, Beelen DW, Fauser AA,
    Volin L, Ruutu T, Uharek L, Fietz T, Knauf W, Hopfenmüller W, Thiel E, Freund M, Casper J.
    Bone Marrow Transplant. 2007 Apr;39(7):389-96.
  21. Toxic epidermal necrolysis after allogeneic haematopoietic stem cell transplantation.
    Hilgendorf I, Casper J, Sviland L, Prall F, Junghanss C, Freund M, Wolff D.
    Bone Marrow Transplant. 2007 Feb;39(4):245-6.
  22. Headache after hematopoietic stem cell transplantation: being aware of chronic bilateral subdural hematoma.
    Hilgendorf I, Wilhelm S, Prall F, Junghanss C, Steiner B, Wolff D, Freund M, Casper J.
    Leuk Lymphoma. 2006 Oct;47(10):2247-9.
  23. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
    Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B, Kahl C, Junghanss C, Hartung G, Casper J, Uharek L, Holler E, Freund M.
    Bone Marrow Transplant. 2006 Sep;38(6):445-51.
  24. T-cell-depleted stem cell boost for the treatment of autoimmune haemolytic anaemia after T-cell-depleted allogeneic bone marrow transplantation complicated by adenovirus infection.
    Hilgendorf I, Wolff D, Wilhelm S, Steiner B, Kiefel V, Hickstein H, Junghanss C, Freund M, Casper J.
    Bone Marrow Transplant. 2006 May;37(10):977-8.
  25. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hähling D, Hartung G, Hilgendorf I, Lück A, Junghanss C, Kahl C, Baumgart J,
    Pichlmeier U, Freund M.
    Dtsch Med Wochenschr. 2005 Sep 23;130(38):2125-9.
  26. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C, Waak M, Knopp A, Kleine HD, Kundt G, Leithäuser M, Hilgendorf I, Wolff D, Casper J, Freund M.
    Neoplasma. 2005;52(5):402-10.
  27. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
    Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J, Leithaeuser M, Hofmeister N, Junghanss C, Casper J, Hartung G,
    Holler E, Freund M.
    Bone Marrow Transplant. 2005 May;35(10):1003-10.
  28. Treosulfan based conditioning for autologous and allogeneic hematopoietic stem cell transplantation.
    Casper J, Freund M.
    Int J Clin Pharmacol Ther. 2004 Nov;42(11):661-2.
  29. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
    Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, Basara N, Fauser AA, Hertenstein B, Mylius HA, Baumgart J,
    Pichlmeier U, Hahn JR, Holler E.
    Bone Marrow Transplant. 2005 Feb;35(3):233-41.
  30. Loss of the GVL effect by loss of the Y-chromosome as putative mechanism of immune escape in ALL.
    Wolff D, Knopp A, Weirich V, Steiner B, Junghanss C, Casper J, Freund M.
    Bone Marrow Transplant. 2005 Jan;35(1):101-2.
  31. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.
    Koenigsmann M, Mohren M, Jentsch-Ullrich K, Franke A, Becker E, Heim M, Freund M, Casper J.
    Bone Marrow Transplant. 2004 Sep;34(6):477-83.
  32. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
    Casper J, Knauf W, Blau I, Ruutu T, Volin L, Wandt H, Schafer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander A, Kroger N, Doelken
    G, Freund M.
    Ann Hematol. 2004;83 Suppl 1:S70-1.
  33. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.
    Wolff D, Steiner B, Stilgenbauer S, Kahl C, Leithäuser M, Junghanss C, Wilhelm S, Kleine HD, Zimmermann R, Hartung G, Casper J,
    Freund M.
    Eur J Haematol. 2004 Feb;72(2):145-8.
  34. First report of a case of meningitis caused by Cryptococcus adeliensis in a patient with acute myeloid leukemia.
    Rimek D, Haase G, Lück A, Casper J, Podbielski A.
    J Clin Microbiol. 2004 Jan;42(1):481-3.
  35. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
    Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, Wegener R, Kleine HD, Wilhelm S, Knopp A, Hartung G, Dölken G, Freund
    M.
    Blood. 2004 Jan 15;103(2):725-31.
  36. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
    Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T,
    Renges H, Ayuk F, Krüll A, Zander A; German Study-group Multiple Myeloma (DSMM).
    Bone Marrow Transplant. 2003 Jun;31(11):973-9.
  37. Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support.
    Kollmannsberger C, Schleucher N, Rick O, Metzner B, Hartmann JT, Schöffski P, Beyer J, Casper J, Sosada M, Schmoll HJ, Böhlke I,
    Meisner C, Kanz L, Bokemeyer C.
    Eur J Cancer. 2003 Apr;39(6):775-82.
  38. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
    Kahl C, Leithäuser M, Wolff D, Steiner B, Hartung G, Casper J, Freund M.
    Ann Hematol. 2002 Nov;81(11):646-50.
  39. Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells.
    Ottinger HD, Müller CR, Goldmann SF, Albert E, Arnold R, Beelen DW, Blasczyk R, Bunjes D, Casper J, Ebell W, Ehninger G, Eiermann T,
    Einsele H, Fauser A, Ferencik S, Finke J, Hertenstein B, Heyll A, Klingebiel T, Knipper A, Kremens B, Kolb HJ, Kolbe K, Lenartz E,
    Lindemann M, Müller CA, Mytilineos J, Niederwieser D, Runde V, Sayer H, Schaefer UW, Schmitz N, Schröder S, Schulze-Rath R,
    Schwerdtfeger R, Siegert W, Thiele B, Zander AR, Grosse-Wilde H.
    Ann Hematol. 2001 Dec;80(12):706-14.
  40. High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize.
    Junghanss C, Leithäuser M, Wilhelm S, Kleine HD, Knopp A, Decker S, Alscher A, Casper J, Köhne CH, Freund M.
    Ann Hematol. 2001 Feb;80(2):96-102.
  41. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
    Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll
    HJ, Derigs G, Gerl A, Berdel WE, Kanz L, Siegert W.
    J Clin Oncol. 2001 Jan 1;19(1):81-8.
  42. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer.
    Kollmannsberger C, Gerl A, Schleucher N, Beyer J, Kuczyk M, Rick O, Casper J, Sosada M, Rie C, Kanz L, Bokemeyer C.
    Anticancer Drugs. 2000 Aug;11(7):535-9.
  43. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
    Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B, Hartmann JT, Schmoll HJ, Kanz L.
    Int J Cancer. 1999 Dec 10;83(6):848-51.
  44. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
    Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L.
    J Clin Oncol. 1999 Feb;17(2):512-6.
  45. Production and pre-clinical significance of haematopoietic peptide growth factors (HPGF) in human non-seminomatous germ cell tumour cell lines.
    Dunn TA, Schmoll HJ, Rie C, Hartmann K, Casper J.
    J Cancer Res Clin Oncol. 1998;124(8):435-43.
  46. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kührer I,
    Illiger HJ, Kempf B, Reichle A, Föller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L,
    Schmoll HJ.
    Semin Oncol. 1998 Apr;25(2 Suppl 4):24-32; discussion 45-8. Review.
  47. [Changes in hemostasis of dogs with acute lymphoblastic leukemia].
    Mischke R, Freund M, Leinemann-Fink T, Eisenberger B, Casper J, Nolte I.
    Berl Munch Tierarztl Wochenschr. 1998 Feb;111(2):53-9. German.
  48. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.
    Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ.
    Scand J Immunol. 1997 Dec;46(6):625-32.
  49. Quantification of additional short arms of chromosome 12 in germ cell tumours using the polymerase chain reaction.
    Malek NP, Casper J, Looijenga LH, Strohmeyer T, Schmoll HJ, Nordheim A, Janknecht R.
    Eur J Cancer. 1997 Aug;33(9):1488-94.
  50. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.
    Dunn TA, Schmoll HJ, Grünwald V, Bokemeyer C, Casper J.
    Invest New Drugs. 1997;15(2):109-14.
  51. Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.
    Dunn TA, Grünwald V, Bokemeyer C, Casper J.
    Invest New Drugs. 1997;15(2):91-8.
  52. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer.
    Dunn TA, Schmoll HJ, Grünwald V, Bokemeyer C, Casper J.
    Anticancer Drugs. 1996 Sep;7(7):795-9.
  53. Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours.
    Andrews PW, Casper J, Damjanov I, Duggan-Keen M, Giwercman A, Hata J, von Keitz A, Looijenga LH, Millán JL, Oosterhuis JW, Pera M,
    Sawada M, Schmoll HJ, Skakkebaek NE, van Putten W, Stern P.
    Int J Cancer. 1996 Jun 11;66(6):806-16.
  54. Management of other non-cisplatin-induced emesis.
    Schmoll HJ, Casper J.
    Oncology. 1996 Jun;53 Suppl 1:51-5. Review.
  55. [10 years transplantation of bone marrow and hematopoietic stem cells in adults at the Hannover Medical School].
    Link H, Diedrich H, Arseniev L, Stoll M, Ebell W, Freund M, Tischler J, Casper J, Hübner G, Schöffski P, Diehl S, Goes A, Jacobs R, Kadar
    J, Stangel W, Müller R, Rittmann KL, Wildfang I, Bucsky P, Bettoni C, Schmidt RE, Riehm H, Poliwoda H.
    Med Klin (Munich). 1996 Apr 12;91 Suppl 3:3-17. German.
  56. Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
    Link H, Arseniev L, Bähre O, Berenson RJ, Battmer K, Kadar JG, Jacobs R, Casper J, Kühl J, Schubert J, Diedrich H, Poliwoda H.
    Blood. 1995 Oct 1;86(7):2500-8.
  57. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
    Arseniev L, Tischler HJ, Battmer K, Südmeier I, Casper J, Link H.
    Bone Marrow Transplant. 1994 Nov;14(5):791-7.
  58. Glycolipids of germ cell tumors: extended globo-series glycolipids are a hallmark of human embryonal carcinoma cells.
    Wenk J, Andrews PW, Casper J, Hata J, Pera MF, von Keitz A, Damjanov I, Fenderson BA.
    Int J Cancer. 1994 Jul 1;58(1):108-15.
  59. 5-ht3 antagonist ondansetron for the treatment of chemotherapy-induced nausea and vomiting in an outpatient population.
    Casper J, Casper S, Kohnewompner C, Bokemeyer C, Hecker H, Schmoll H.
    Int J Oncol. 1994 Jun;4(6):1283-9.
  60. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
    Bokemeyer C, Schmoll HJ, Ludwig E, Harstrick A, Dunn T, Casper J.
    Br J Cancer. 1994 May;69(5):863-7.
  61. No growth-stimulation of heterotransplanted human testicular cancer cell-lines by recombinant human granulocyte-macrophage colony-stimulating factor (gm-csf).
    Bokemeyer C, Schmoll H, Casper J, Kuczyk M, Poliwoda H.
    Int J Oncol. 1993 Jul;3(1):77-80.
  62. A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma.
    Stahl M, Wilke H, Schmoll HJ, Schöber C, Diedrich H, Casper J, Freund M, Poliwoda H.
    Ann Oncol. 1992 Feb;3(2):167-8.
  63. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma.
    Harstrick A, Schmoll HJ, Wilke H, Köhne-Wömpner CH, Stahl M, Schöber C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, et al.
    J Clin Oncol. 1991 Sep;9(9):1549-55.
  64. Cellular oncogenes in human teratocarcinoma cell lines.
    Tesch H, Fürbass R, Casper J, Lyons J, Bartram CR, Schmoll HJ, Bronson DL.
    Int J Androl. 1990 Oct;13(5):377-88.
  65. Interaction of human embryonal carcinoma cells and differentiated derivatives in vitro with simian virus 40, human adenovirus type 7, or PARA.
    Bronson DL, Lanford RE, Casper J, Wians FH Jr.
    Exp Cell Res. 1990 Jan;186(1):60-5.
  66. Phase II study of carboplatin in untreated inoperable advanced stomach cancer.
    Preusser P, Wilke H, Achterrath W, Lenaz L, Stahl M, Casper J, Meyer HJ, Meyer J, Blum M, Schmoll HJ.
    Eur J Cancer. 1990;26(10):1108-9.
  67. Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents.
    Harstrick A, Schmoll HJ, Casper J, Wilke H, Poliwoda H.
    Eur J Cancer. 1990;26(8):898-901.
  68. Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines.
    Harstrick A, Casper J, Köhne-Wömpner H, Wilke H, Schmoll HJ, Poliwoda H.
    Invest New Drugs. 1990;8 Suppl 1:S19-24.
  69. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in
    vivo and in vitro.
    Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Schmoll HJ.
    Cancer. 1989 Mar 15;63(6):1079-83.
  70. Characterization of rearranged Y chromosomes in human testicular tumor cell lines.
    Arnemann J, Gradl G, Casper J, Schmoll HJ, Schmidtke J, Fonatsch C.
    Cancer Genet Cytogenet. 1989 Feb;37(2):141-51.
  71. Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.
    Harstrick A, Casper J, Schmoll HJ.
    Int J Androl. 1987 Feb;10(1):139-45.
  72. Cell lines of human germinal cancer.
    Casper J, Schmoll HJ, Schnaidt U, Fonatsch C.
    Int J Androl. 1987 Feb;10(1):105-13.
  73. Comparison of endogenous lectins in human embryonic carcinoma and yolk sac carcinoma.
    Gabius HJ, Engelhardt R, Casper J, Schmoll HJ, Nagel GA, Cramer F.
    Tumour Biol. 1986;6(5):471-82.
  74. Cell surface lectins of transplantable human teratocarcinoma cells: purification of a new mannan-specific endogenous lectin.
    Gabius HJ, Engelhardt R, Casper J, Reile D, Schumacher S, Schmoll HJ, Graupner G, Cramer F.
    Tumour Biol. 1985;6(2):145-56.
  75. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
    Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, Bornhäuser M, Ehninger G, Berdel WE, Baumgart J, Harstrick A,
    Bojko P, Wolf HH, Schindler AE, Seeber S.
    Clin Cancer Res. 2000 Nov;6(11):4209-16.


Klinikum Oldenburg | Medizinischer Campus Universität Oldenburg

Karriereportal

Jobs.
Karriere.
Ausbildung.
Jetzt bewerben >

Hinweis: Die aufgeführten Qualifikationen, Publikationen und Werdegänge unserer Mitarbeiter sind nicht unbedingt umfassend/vollständig aufgeführt.